Optimizing Adjuvant Therapy in EGFR-Mutated NSCLC
 |
| Optimizing Adjuvant EGFR-Targeted Therapy in Early-Stage EGFR-Mutated NSCLCs This program will focus on the evolving role of adjuvant targeted therapy in early-stage EGFR-mutated non–small cell lung cancer, with an emphasis on translating clinical trial evidence into real-world practice. |
|
ADVERTISEMENT  |
|
Featured Video |
 |
| Evolving Adjuvant Therapy in Early-Stage EGFR-Mutated NSCLC: Insights From ADAURA Experts explain how adjuvant osimertinib changes post-surgery EGFR lung cancer care, from rapid testing to real-world adherence. |
|